Therapy News and Research

RSS

Pluristem's PLX cells exhibit potential to treat accidental and intentionally induced muscle injuries

Pluristem Therapeutics, Inc. and the Berlin-Brandenburg Center for Regenerative Therapies (BCRT), in cooperation with the Charite - University of Medicine in Berlin,today announced the results of a pre-clinical study demonstrating that the local administration of PLX cells following muscle injury resulted in significant improvement in the recovery of muscle function when compared with the control group. This

2 Mar 2011

Neuralstem announces initiation of NSI-189 Phase Ia trial for major depressive disorder

Neuralstem, Inc. announced that the first subject was dosed yesterday in a Phase Ia trial to evaluate the safety of its drug, NSI-189, which is being developed for the treatment of major depressive disorder and other psychiatric indications. NSI-189 is the lead compound in Neuralstem's neurogenerative small molecule drug platform. This phase of the trial is in healthy volunteers and seeks to determine the maximum tolerated single dose.

2 Mar 2011

Scientists at retrovirus conference present findings on microbicide gel, Truvada, male circumcision, ART care by nurses

At the annual Conference on Retroviruses and Opportunistic Infections (CROI) in Boston on Monday, researchers "suggested the potential" of a gel containing the antiretroviral drug tenofovir to reduce the risk of anal HIV transmission, TIME's "Healthland" blog reports.

2 Mar 2011

EPO to grant patent for Apricus MycoVa product to treat nail fungus

Apricus Biosciences, Inc. announced today that the European Patent Office will grant a patent for the company's MycoVa product for treating onychomycosis.

2 Mar 2011

Psychologists develop cognitive-bias modification to help alcoholics stay sober

Alcoholism is a tough addiction to kick. Eventually, most people return to drinking. But some Dutch and German psychological scientists have tested a short-term regime that promises to help alcoholics stay sober. Their study is published in Psychological Science, a journal of the Association of Psychological Science.

2 Mar 2011

NCI sponsors multi-center phase 2 study of entinostat-anastrozole combination in triple negative breast cancer

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, announced the National Cancer Institute (NCI) will sponsor a multi-center phase 2 study of Syndax's lead product entinostat, a novel inhibitor of histone deacetylases (HDAC), and anastrozole, an aromatase inhibitor, in postmenopausal women with operable triple negative breast cancer to evaluate biomarkers and surrogates for response.

2 Mar 2011

OneWorld Health receives FDA clearance for iOWH032 phase 1 trials to treat secretory diarrhea

The Institute for OneWorld Health (iOWH) announced a major milestone in the fight against cholera. The Food and Drug Administration (FDA) granted iOWH permission to begin phase 1 trials for iOWH032, a drug to treat secretory diarrhea. This is the first submission of an Investigational New Drug application for a completely new chemical entity by a non-profit of this size to receive such rapid FDA clearance, and it could be the first synthetic drug of its kind for diarrheal diseases.

2 Mar 2011

Bayhill's BHT-3034 receives FDA IND clearance for treatment of myasthenia gravis

Bayhill Therapeutics Inc, a clinical-stage biopharmaceutical company utilizing its proprietary BHT-DNA™ platform to develop novel and targeted autoimmune and immune-mediated disease treatments, today announced the successful clearance of an IND with the US FDA for BHT-3034, a disease-modifying DNA plasmid vaccine immunotherapy for patients with the autoimmune neuromuscular junction disease myasthenia gravis.

1 Mar 2011

New therapeutic strategy improves superior renal function after kidney transplantation

Researchers at Charité - Universitätsmedizin Berlin, together with 16 other transplant centers in Germany and Switzerland successfully tested a new therapeutic strategy that allows for superior renal function after kidney transplantation. The results were published online in the journal "The Lancet".

1 Mar 2011

QLT fourth quarter revenues decrease 7.3% to $10.0 million

QLT Inc. today reported financial results for the fourth quarter ended December 31, 2010 and full year 2010 as well as issued its guidance for 2011. Unless specified otherwise, all amounts are in U.S. dollars and in accordance with U.S. GAAP.

1 Mar 2011

San Diego Hospice is California's first provider of unique children care program

The Comprehensive Care Management Programs at San Diego Hospice celebrates one year as California's first provider of Partners for Children. This unique state-funded program allows chronically ill children on Medi-Cal and CCS to receive pain and symptom management services, or palliative care, at home.

1 Mar 2011

New study: No decline in breast cancer incidence rates among U.S. white women

A sharp decline in breast cancer incidence rates among non-Hispanic white women in the U.S. after a dramatic drop in the use of postmenopausal hormone therapy did not continue through 2007, according to a new study from the American Cancer Society and the National Cancer Institute.

1 Mar 2011

Survey finds social networking sites associated with one in five divorces in the US

If you're single, Facebook and other social networking sites can help you meet that special someone. However, for those in even the healthiest of marriages, improper use can quickly devolve into a marital disaster.

1 Mar 2011

FDA approves Forest Labs' Daliresp to treat COPD

Forest Laboratories, Inc. announced today that Daliresp was approved by the U.S. Food and Drug Administration as a treatment to reduce the risk of chronic obstructive pulmonary disease exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.

1 Mar 2011

New cell therapy can reverse effect of 'bad' LDL cholesterol and reduce atherosclerosis

Researchers at the Swedish medical university Karolinska Institutet have shown in a new study on mice, that cell therapy can be used to reverse the effect of 'bad' LDL cholesterol and reduce the inflammation that leads to atherosclerosis.

1 Mar 2011

Decision Resources: 52% of surveyed cardiologists identify furosemide as efficacious acute heart failure therapy

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the highest proportion of surveyed cardiologists identify furosemide as the most efficacious agent for the treatment of acute heart failure when compared to other available therapies.

1 Mar 2011

New guidelines to address major clinical issues encountered in treatment of Barrett's esophagus

Endoscopic removal of pre-cancerous cells in patients with confirmed, high-risk Barrett's esophagus is recommended rather than surveillance, according to a new "Medical Position Statement on the Management of Barrett's Esophagus," published by the American Gastroenterological Association (AGA) Institute. The medical position statement was published in Gastroenterology, the official journal of the AGA Institute.

1 Mar 2011

Scientists to launch international working group to tackle HIV

More than 30 scientists gathered for a one-day meeting prior to the 18th Conference on Retroviruses and Opportunistic Infections to launch an international working group on HIV reservoirs and strategies to control them.

1 Mar 2011

New personalized therapy fools cancer cells into killing themselves

A Wayne State University School of Medicine physician-researcher has developed a personalized therapy to treat a wide range of cancers. The treatment is based on a naturally occurring human enzyme that has been genetically modified to fool cancer cells into killing themselves.

1 Mar 2011

HCI creates Pediatric Cancer Late Effects Clinic to help manage long-term issues of treatment

Although cancer in children is rare, more than 10,000 children in the United States are diagnosed with some form of the disease every year. If these children survive, studies have found that more than two-thirds develop at least one late-effect of treatment, which can include additional cancers, fertility and heart problems, limited limb function, and hearing loss.

1 Mar 2011

Therapy News and Research

Pluristem's PLX cells exhibit potential to treat accidental and intentionally induced muscle injuries

Neuralstem announces initiation of NSI-189 Phase Ia trial for major depressive disorder

Scientists at retrovirus conference present findings on microbicide gel, Truvada, male circumcision, ART care by nurses

EPO to grant patent for Apricus MycoVa product to treat nail fungus

Psychologists develop cognitive-bias modification to help alcoholics stay sober

NCI sponsors multi-center phase 2 study of entinostat-anastrozole combination in triple negative breast cancer

OneWorld Health receives FDA clearance for iOWH032 phase 1 trials to treat secretory diarrhea

Bayhill's BHT-3034 receives FDA IND clearance for treatment of myasthenia gravis

New therapeutic strategy improves superior renal function after kidney transplantation

QLT fourth quarter revenues decrease 7.3% to $10.0 million

San Diego Hospice is California's first provider of unique children care program

New study: No decline in breast cancer incidence rates among U.S. white women

Survey finds social networking sites associated with one in five divorces in the US

FDA approves Forest Labs' Daliresp to treat COPD

New cell therapy can reverse effect of 'bad' LDL cholesterol and reduce atherosclerosis

Decision Resources: 52% of surveyed cardiologists identify furosemide as efficacious acute heart failure therapy

New guidelines to address major clinical issues encountered in treatment of Barrett's esophagus

Scientists to launch international working group to tackle HIV

New personalized therapy fools cancer cells into killing themselves

HCI creates Pediatric Cancer Late Effects Clinic to help manage long-term issues of treatment

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News